RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 65 filers reported holding RA PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $213,358,000 | +1.3% | 4,444,070 | -1.0% | 0.01% | +25.0% |
| Q4 2019 | $210,637,000 | +89.9% | 4,488,324 | -4.3% | 0.01% | +60.0% |
| Q3 2019 | $110,918,000 | -9.1% | 4,689,992 | +15.5% | 0.01% | 0.0% |
| Q2 2019 | $122,061,000 | +71.8% | 4,059,169 | +27.9% | 0.01% | +66.7% |
| Q1 2019 | $71,067,000 | +47.6% | 3,172,586 | +19.9% | 0.00% | +50.0% |
| Q4 2018 | $48,142,000 | +29.8% | 2,645,261 | +29.0% | 0.00% | 0.0% |
| Q3 2018 | $37,084,000 | +142.4% | 2,049,933 | +33.3% | 0.00% | +100.0% |
| Q2 2018 | $15,297,000 | +150.1% | 1,537,331 | +33.5% | 0.00% | – |
| Q1 2018 | $6,117,000 | -24.5% | 1,151,744 | +20.9% | 0.00% | – |
| Q4 2017 | $8,097,000 | -13.9% | 952,580 | +47.9% | 0.00% | – |
| Q3 2017 | $9,405,000 | -19.2% | 644,128 | +3.7% | 0.00% | -100.0% |
| Q2 2017 | $11,644,000 | +58.5% | 621,329 | +80.1% | 0.00% | – |
| Q1 2017 | $7,346,000 | +2725.4% | 345,041 | +1917.0% | 0.00% | – |
| Q4 2016 | $260,000 | – | 17,107 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |